Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

NCT07594431 | Not Yet Recruiting Phase 2 FDA Device

• 1 other identifier: IRB-86384
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)

Conditions

Metastases; Metastatic Cancer

Keywords

LATTICE Radiotherapy; Palliative Radiotherapy

Outcome Measures

Primary Outcomes (1)

• Percent Tumor Volume Reduction Following Radiotherapy

  Radiographic response defined as percent tumor volume reduction 90 +/- 20 days following radiotherapy

  90 +/- 20 days following radiotherapy

Study Arms (2)

LATTICE Radiotherapy

EXPERIMENTAL

Participants receive 5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

Radiation: LATTICE Radiotherapy

Standard Radiotherapy

ACTIVE COMPARATOR

Participants receive standard radiotherapy (25 Gy in 5 fractions)

Radiation: Standard radiotherapy

Interventions

LATTICE Radiotherapy RADIATION

5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

LATTICE Radiotherapy

Standard radiotherapy RADIATION

Standard radiotherapy delivered to 25 Gy in 5 fractions.

Standard Radiotherapy

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer
• One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \>2.5 cm in short axis
• Age ≥12
• ECOG Performance Status 0-2
• For patients age 12-16, Lansky Play-Performance score 50-100
• Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential
• All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.

You may not qualify if:

• Prior radiation therapy to the tumor to be treated
• Active pregnancy
• Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome
• The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

Sponsors & Collaborators

• Stanford University: lead

Study Sites (1)

Stanford University

Palo Alto, California, 94304, United States

Location

MeSH Terms

Conditions

Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Michael Gensheimer, MD

  Stanford University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jamie Wang

CONTACT

650-497-4354; jwang97@stanford.edu

Camellia Djebroun

CONTACT

650-736-5564; cdjebrou@stanford.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2026
• First Posted: May 18, 2026
• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): August 1, 2028
• Last Updated: May 18, 2026

Record last verified: 2026-05

Locations

US (1)